Innoviva's royalties portfolio centers on respiratory assets partnered with Glaxo Group Limited (GSK), providing ongoing revenue from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® sales. Through its specialty therapeutics division, Innoviva commercializes critical care and infectious disease products including GIAPREZA, XERAVA, XACDURO, and ZEVTERA, with recent FDA approval of NUZOLVENCE for uncomplicated urogenital gonorrhea.
Cyborg Score Rationale
Innoviva reported strong 2025 results with 15% revenue growth to $411.3M, net income of $271.2M, IST U.S. net product sales grew 47% YoY to $119.2M, and royalty revenue was $250.3M. The company has a $125M share repurchase program, strategic asset portfolio valued at $614.0M, and $550.9M in cash and equivalents.
Top Insights
FDA approved NUZOLVENCE® (zoliflodacin), a first-in-class, single-dose oral medication for uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older.
IST U.S. net product sales grew 47% YoY to $119.2M, demonstrating strong commercialization momentum.
Company executing $125M share repurchase program with $550.9M in cash position.
Portfolio of strategic healthcare assets includes equity and long-term investments in companies developing therapies in infectious disease and neurological conditions.
Named Competitors
BREO ELLIPTA / ANORO ELLIPTA — Respiratory combination therapies in same product class
Other vasopressors and antibiotics — Competitive products in critical care and infectious disease
Recent Developments
(February 2026) Participated in Oppenheimer 36th Annual Healthcare Life Sciences Conference
(December 2025) Reported full year 2025 financial results with 15% revenue growth to $411.3M and net income $271.2M
(2025) FDA approved NUZOLVENCE (zoliflodacin) for uncomplicated urogenital gonorrhea
Open the full interactive Innoviva, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.